NanoViricides to file IND after positive results in FluCide-1 studies

By Lisa Kerner

Erie, Pa., March 20 - NanoViricides, Inc. said additional results from its FluCide-1 efficacy studies will lead to the company's filing of an Investigational New Drug application with the Food and Drug Administration.

"The results were so positive that with an appropriate dosage protocol, it may be possible to save human lives even in bird flu cases using this test nanoviricide itself," chief regulatory officer Dr. Krishna Menon said in a company news release.

In the Fast Protocol study in mice, a nanomicelle was attached to a broad-spectrum, anti-influenza test ligand (virus targeting molecule), forming a nanoviricide.

The mice were infected with high levels of a human influenza virus, with an untreated survival period of seven days. A sub-group of the mice were treated with the test nanoviricide 24 hours after infection.

According to NanoViricides, the survival time of treated mice was increased significantly at low and safe dosage levels. Results also suggested that the dosage can be increased without significant adverse effects.

The company said that with this platform it can attack multiple subtypes of influenza or attack a specific virus subtype, such as highly pathogenic avian influenza and H5N1.

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The company is located in West Haven, Conn.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.